Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 7/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.34 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL7158197 | 1.00 | AKR1C3 (0.46) | AKR1C3APEX1TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL7133171 | 0.89 | AKR1C3 (0.55) | AKR1C3APEX1TBXAS1TUBB1PTGS1 | |
| SCHEMBL7133176 | 0.89 | AKR1C3 (0.55) | AKR1C3APEX1TBXAS1TUBB1PTGS1 | |
| Guanidine SCHEMBL7163058 | 0.83 | AKR1C3 (0.55) | AKR1C3TBXAS1FBP1PTGS2 | |
| Guanidine SCHEMBL7163063 | 0.83 | AKR1C3 (0.55) | AKR1C3TBXAS1FBP1PTGS2 | |
| Guanidine SCHEMBL7159629 | 0.82 | AKR1C3 (0.37) | AKR1C3APEX1TBXAS1PRSS1TMPRSS15 | |
| Guanidine SCHEMBL7159623 | 0.82 | AKR1C3 (0.37) | AKR1C3APEX1TBXAS1PRSS1TMPRSS15 | |
| SCHEMBL27927621 | 0.80 | SLC9A1 (0.39) | AKR1C3APEX1SLC9A1SLC9A3SLC9A2 | |
| Hydrochloric Acid SCHEMBL7158195 | 0.80 | TUBB1 (0.33) | SLC9A1SLC9A3SLC9A2FBP1TUBB1 | |
| Guanidine SCHEMBL8058713 | 0.80 | RPS6KA3 (0.49) | AKR1C3TBXAS1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6504057-B2 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-01-07 | — | — | US | disclosed |
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | HOECHST AKTIENGESELLSCHAFT | 2002-09-05 | — | — | US | disclosed |
| US-20010020042-A1 | Cardiovascular disorders | HOECHST AKTIENGESELLSCHAFT | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123529-A1 | Anti-arrhythmia, -ischemic, -proliferative and -diabetic agents; cardiotonic, necrosis; angina pectoris; peripheral and central nervous systems; protecting/preserving organs; inhibition of Na+/H+ exchange; diagnosis hypertonia | TNNI3, SLC5A1, TNNC1 | AKR1C3 613/4885APEX1 2554/4885TBXAS1 2556/4885 |
| US-20010020042-A1 | Cardiovascular disorders | SLC5A1, SLC9A1, SLC28A1 | AKR1C3 393/4885APEX1 971/4885TBXAS1 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.